Positive results of the Phase II Mirakle study

  • Dec 5, 2024

The study demonstrated the non-inferiority of NTC014 - antibiotic and NSAID-compared to an antibiotic alone for bacterial conjunctivitis, despite a lower dose of antibiotic. This drug fulfills NTC's mission to rationalize the use of antibiotics.

Interview by Riccardo Carbucicchio, CEO for Life Science Review

  • Nov 6, 2024

In the interview with Life Science Review, NTC CEO Riccardo Carbucicchio highlighted NTC's commitment to producing drugs that fill patients' unmet medical needs...

NTC grants Chinoin the license and distribution rights in Mexico and LatAm for its innovative therapeutic solution for colonoscopy preparation

  • Oct 24, 2024

The deal represents an important step for the internationalization of NTC015, developed to address unmet medical needs and improve patient compliance.

NTC launches Imperial, the new eye drops product line on THE PATIENT’S SIDE

  • Oct 7, 2024

NTC, an international pharmaceutical company headquartered in Milan, Italy, announced today to have embraced a strategic partnership with Silgan Dispensing Systems